Table 1 Indications and response rates of infliximab induction therapy
Indication of IFX therapy | Number and rate of disease type | Response rate after induction |
|---|---|---|
Therapy-refractory CD | 114 (31.4%) | 83.3% |
By localization | ||
Ileum | 10 (8.77%) | |
Colon | 29 (25.4%) | 79.3% |
Ileo-colonic | 46 (40.4%) | 87.0% |
Ileo-colonic and small bowel | 28 (24.6%) | 78.6% |
Oesophagus | 1 (0.9%) | 1/1 |
Therapy-refractory and fistulizing | 16 (4.4%) | 93.8% |
Fistulizing | 195 (53.7%) | 85.6% |
By localization | ||
Perianal | 148 (75.9%) | 91.2% |
Enterocutaneous | 24 (12.3%) | 87.5% |
Enterovaginal | 11 (5.6%) | 9/11 |
Other | 12 (6.2%) | 7/12 |
Mixed | 7 (3.6%) | 5/7 |
Steroid dependent | 26 (7.2%) | 92.3% |
By localization | ||
Ileum | 3 (11.5%) | 3/3 |
Colon | 4 (15.4%) | 4/4 |
Ileo-colic | 19 (73.1%) | 17/19 |
Metastatic | 5 (0.1%) | Na. |
Other | 7 (0.2%) | Na. |